FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136907> ?p ?o ?g. }

• W4324136907 endingPage "TPS283" @default.
• W4324136907 startingPage "TPS283" @default.
• W4324136907 abstract "TPS283 Background: There is no clear standard of care for biochemically recurrent prostate cancer (PCa) with positron emission tomography (PET)-detected oligometastases and normal conventional imaging (CIM). Phase II trials show that stereotactic ablative body radiotherapy (SABR) to oligometastases may delay cancer progression and initiation of androgen deprivation therapy (ADT) and its untoward effects. ADT with radiation prolongs survival in locally advanced PCa and in CIM metastatic PCa. However, there is a knowledge gap about timing and benefit vs toxicity of ADT with SABR in early oligometastatic PCa. NRG GU011 (PROMETHEAN) is a randomized phase II trial of SABR with or without relugolix for early PET-detected recurrent oligometastatic PCa. This study aims to evaluate the impact of relugolix, a novel oral gonadotropin-releasing hormone receptor antagonist, when combined with SABR to oligometastases. Relugolix allows for rapid testosterone recovery and is associated with fewer cardiovascular events when compared to leuprolide and is hypothesized to have low late ADT toxicity. GU011 will provide patients and their physicians data on the relative risks and benefits of early or delayed ADT in this setting. Methods: NRG-GU011 NCT# 05053152 is a randomized phase II double-blinded, placebo-controlled trial with randomization to SABR + 6 months placebo vs SABR + 6 months relugolix. Eligible patients have biochemical recurrence after prior curative intent radiation or surgery for localized PCa, PSA < 10 ng/mL, negative CIM and 1-5 PET-evident metastases (≥1 extrapelvic). SABR is delivered in 1-5 fractions to BED >100 Gy1.5, followed by placebo or relugolix 120mg daily for 6 months. Patients will then be followed with imaging at time of biochemical recurrence. The planned sample size of 260 patients (130 per arm) will provide 85% power to detect a hazard ratio of 0.65 for radiographic progression-free survival (rPFS), based on a one-sided test at alpha 0.10. Planned enrollment is predicted at 8 patients per month with an estimated study completion date of late 2026. The primary endpoint is CIM rPFS. Secondary endpoints include PET-based rPFS, sexual and hormonal quality of life (QoL) assessed by EPIC-26, other QoL measures from EQ5D-5L, EORTC QLQ-30 and PROMIS Fatigue, and between-group comparisons of time to salvage therapy, castration-resistance, local progression (SABR-targeted lesion), biochemical progression, distant metastases, prostate cancer-specific mortality, metastasis-free survival, and overall survival. We also aim to determine adverse event rates for both treatment arms and evaluate genomic and blood markers of treatment response. This study opened in December 2021. Clinical trial information: NCT05053152 ." @default.
• W4324136907 created "2023-03-15" @default.
• W4324136907 creator A5000044683 @default.
• W4324136907 creator A5006174923 @default.
• W4324136907 creator A5019525982 @default.
• W4324136907 creator A5023914087 @default.
• W4324136907 creator A5036138286 @default.
• W4324136907 creator A5038171309 @default.
• W4324136907 creator A5052154893 @default.
• W4324136907 creator A5070623757 @default.
• W4324136907 creator A5072458448 @default.
• W4324136907 creator A5077358252 @default.
• W4324136907 creator A5085318253 @default.
• W4324136907 creator A5087189944 @default.
• W4324136907 date "2023-02-20" @default.
• W4324136907 modified "2023-10-17" @default.
• W4324136907 title "NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN)." @default.
• W4324136907 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.tps283" @default.
• W4324136907 hasPublicationYear "2023" @default.
• W4324136907 type Work @default.
• W4324136907 citedByCount "0" @default.
• W4324136907 crossrefType "journal-article" @default.
• W4324136907 hasAuthorship W4324136907A5000044683 @default.
• W4324136907 hasAuthorship W4324136907A5006174923 @default.
• W4324136907 hasAuthorship W4324136907A5019525982 @default.
• W4324136907 hasAuthorship W4324136907A5023914087 @default.
• W4324136907 hasAuthorship W4324136907A5036138286 @default.
• W4324136907 hasAuthorship W4324136907A5038171309 @default.
• W4324136907 hasAuthorship W4324136907A5052154893 @default.
• W4324136907 hasAuthorship W4324136907A5070623757 @default.
• W4324136907 hasAuthorship W4324136907A5072458448 @default.
• W4324136907 hasAuthorship W4324136907A5077358252 @default.
• W4324136907 hasAuthorship W4324136907A5085318253 @default.
• W4324136907 hasAuthorship W4324136907A5087189944 @default.
• W4324136907 hasConcept C106159729 @default.
• W4324136907 hasConcept C121608353 @default.
• W4324136907 hasConcept C126322002 @default.
• W4324136907 hasConcept C126894567 @default.
• W4324136907 hasConcept C141071460 @default.
• W4324136907 hasConcept C142724271 @default.
• W4324136907 hasConcept C143998085 @default.
• W4324136907 hasConcept C162324750 @default.
• W4324136907 hasConcept C187625094 @default.
• W4324136907 hasConcept C204787440 @default.
• W4324136907 hasConcept C27081682 @default.
• W4324136907 hasConcept C2776235491 @default.
• W4324136907 hasConcept C2777899217 @default.
• W4324136907 hasConcept C2779466945 @default.
• W4324136907 hasConcept C2780192828 @default.
• W4324136907 hasConcept C509974204 @default.
• W4324136907 hasConcept C71924100 @default.
• W4324136907 hasConcept C85393063 @default.
• W4324136907 hasConcept C91602232 @default.
• W4324136907 hasConceptScore W4324136907C106159729 @default.
• W4324136907 hasConceptScore W4324136907C121608353 @default.
• W4324136907 hasConceptScore W4324136907C126322002 @default.
• W4324136907 hasConceptScore W4324136907C126894567 @default.
• W4324136907 hasConceptScore W4324136907C141071460 @default.
• W4324136907 hasConceptScore W4324136907C142724271 @default.
• W4324136907 hasConceptScore W4324136907C143998085 @default.
• W4324136907 hasConceptScore W4324136907C162324750 @default.
• W4324136907 hasConceptScore W4324136907C187625094 @default.
• W4324136907 hasConceptScore W4324136907C204787440 @default.
• W4324136907 hasConceptScore W4324136907C27081682 @default.
• W4324136907 hasConceptScore W4324136907C2776235491 @default.
• W4324136907 hasConceptScore W4324136907C2777899217 @default.
• W4324136907 hasConceptScore W4324136907C2779466945 @default.
• W4324136907 hasConceptScore W4324136907C2780192828 @default.
• W4324136907 hasConceptScore W4324136907C509974204 @default.
• W4324136907 hasConceptScore W4324136907C71924100 @default.
• W4324136907 hasConceptScore W4324136907C85393063 @default.
• W4324136907 hasConceptScore W4324136907C91602232 @default.
• W4324136907 hasIssue "6_suppl" @default.
• W4324136907 hasLocation W43241369071 @default.
• W4324136907 hasOpenAccess W4324136907 @default.
• W4324136907 hasPrimaryLocation W43241369071 @default.
• W4324136907 hasRelatedWork W2044284566 @default.
• W4324136907 hasRelatedWork W2154491681 @default.
• W4324136907 hasRelatedWork W2402249956 @default.
• W4324136907 hasRelatedWork W2545489389 @default.
• W4324136907 hasRelatedWork W2590008096 @default.
• W4324136907 hasRelatedWork W2756688586 @default.
• W4324136907 hasRelatedWork W4281959228 @default.
• W4324136907 hasRelatedWork W4319748405 @default.
• W4324136907 hasRelatedWork W93186087 @default.
• W4324136907 hasRelatedWork W193188344 @default.
• W4324136907 hasVolume "41" @default.
• W4324136907 isParatext "false" @default.
• W4324136907 isRetracted "false" @default.
• W4324136907 workType "article" @default.